Company intelligence / Profile preview

iX Biopharma

Ownership: Private
Development stage: Commercial

Overview

iX Biopharma has developed a proprietary sublingual wafer platform ("WaferiX") enabling rapid and efficient drug absorption. Lead clinical assets include Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. Wafesil (sildenafil wafer) and Silcap are registered in Australia; Silcap also approved in Singapore. Xativa is the first freeze-dried sublingual medicinal cannabis wafer. The company recently reported positive preclinical results for a semaglutide sublingual wafer with significantly improved bioavailability over oral semaglutide tablets[2][3].

Therapeutic areas: OtherMen's HealthEndocrinologyNeurology
Modalities: Small moleculePeptidesMedicinal cannabisNutraceuticals
Industry: Biotech

Drug pipeline

7 assets

iXB 321

Preclinical

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on iX Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iX Biopharma.

Explore the full profile